AMITIZA

This brand name is authorized in United States. It is also authorized in Brazil, Japan, Singapore.

Active ingredients

The drug AMITIZA contains one active pharmaceutical ingredient (API):

1	Lubiprostone UNII 7662KG2R6K - LUBIPROSTONE
	Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation (CIC).
	Read more about Lubiprostone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AMITIZA Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A06AX03	Lubiprostone	A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AX Other laxatives
Discover more medicines within A06AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501120060029907, 501120060030007, 501120060030107, 501120060030207, 501120060030307, 501120060030407, 501120060030507, 501120060030607
JP	医薬品医療機器総合機構	2359006M1025, 2359006M2021
SG	Health Sciences Authority	15329P, 15330P
US	FDA, National Drug Code	35356-500, 63629-6398, 64764-080, 64764-240